Summary Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.
Retinoids have been shown in vitro and in animal experiments to have inhibitory activity against a wide range of solid tumours. The single-agent activity in man has been disappointing apart from in acute promyelocytic leukaemia (Smith et al., 1992) . However, combination therapy with interferon has shown considerable activity against cervical carcinoma (Lippman et al., 1992) . This has suggested that retinoids should be tested with a variety of other biologically active agents. The vitamin D metabolite, 1,25 dihydroxy vitamin D3 (calcitriol), is one agent that has shown additive or synergistic activity on differentiation, angiogenesis and proliferation when combined with retinoids . A trial of alphacalcidol in low-grade non-Hodgkin's lymphoma showed evidence of response in four of seven patients (Rains et al., 1991) . Topical calcipotriol produced partial responses in three of 14 patients with drug-resistant breast carcinoma (Bower et al., 1991) . The combination of isotretinoin (13 cis-retinoic acid) and calcitriol has been shown to lead to remissions in some patients with cutaneous T-cell lymphoma, basal cell and squamous cell carcinomas (French et al., 1994; Majewski et al., 1994; Thomsen, 1995) .
Ovarian cancer was chosen for the investigation of retinoids as all-trans retinoic acid causes growth inhibition in ovarian carcinoma cell lines (Caliaro et al., 1994) . Additional factors favouring ovarian carcinoma are that it is rarely associated with hypercalcaemia, and relapsing tumour detected by rising levels of serum CA 125 can be asymptomatic for several months (Van der Burg et al., 1990) . These patients can, therefore, receive the isotretinoin and calcitriol combination for a sufficient period, so that stabilisation of disease owing to tumour differentiation can be manifested. CA 125 is elevated in over 90% of patients with advanced ovarian cancer and has been shown to predict tumour response and progression accurately (Rustin et al., 1993 (Rustin et al., , 1996a , but this is, to our knowledge, the first trial in which it has been used as the main mediator of efficacy. 'Actual weeks receiving both isotretinoin and calcitriol, excluding breaks owing to hypercalcaemia. Many studies have included analysis of CA 125 trends during therapy, but we believe that this is the first study in which CA 125 was the main method of tumour assessment. We have previously shown that response to initial chemotherapy can be accurately measured by using precise definitions based on either a 50% or 75% fall in CA 125 levels (Rustin et al., 1996a) . These response definitions based on CA 125 have been studied in phase II trials of seven different new drugs and in each case have clearly shown which drugs are active and which are inactive (Rustin et al., 1996c) . The lack of responses according to CA 125 in the present study can. therefore, be relied upon. Because we were also looking for disease stabilisation, we examined the rate of rise of CA 125 during therapy and compared this slope with a similar period before therapy. The lack of significant difference between the regression slopes plus the observation of clinical progression in 11 of 16 evaluable patients is evidence that the vitamin combination did not induce stabilisation. The observation that a >25% rise in CA 125 levels was seen in 12 of 16 evaluable women during the therapy is further evidence of tumour progression.
